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Introduction
The genus Ebolavirus (EBOV) in the Filoviridae family 
contains five distinct species [1]. Ebolaviruses are known 
for their ability to cause devastating viral hemorrhagic 
fever outbreaks in humans and great apes, but the natural 
reservoir for EBOV has remained elusive for many years. 
The recent detection of EBOV antibodies and viral RNA 
in several African fruit bat species indicated their role as 
a natural reservoir for EBOV [2-5].
EBOV was discovered in humans during two con  cur-
rent  outbreaks  in  1976.  One  of  these  occurred  in  the 
Democratic Republic of Congo and was caused by Zaire 
ebolavirus  (ZEBOV)  [6],  whereas  the  other,  unrelated 
out  break that occurred in Sudan was caused by Sudan 
ebolavirus (SEBOV; Table 1) [7]. ZEBOV caused several 
more outbreaks between 1994 and 2008 in Gabon, the 
Democratic  Republic  of  Congo  and  the  Republic  of 
Congo, with a case-fatality rate ranging from 60% to 90%. 
SEBOV  reemerged  in  Sudan  in  1979  and  2004  and  in 
Uganda in 2000 to 2001. SEBOV has a case-fatality rate of 
40 to 60% [8].
Reston  ebolavirus  (REBOV)  was  discovered  in  1989 
during  a  disease  outbreak  in  cynomolgus  macaques 
imported into the US from the Philippines [9]. Outbreaks 
of REBOV occurred again in 1990, 1992 and 1996 in the 
US and Italy in cynomolgus macaques imported from the 
same  facility  in  the  Philippines  and,  in  2008,  REBOV 
emerged in domestic pigs in the Philippines [10]. REBOV 
has not yet been associated with disease in humans, but 
there is evidence for REBOV infection in humans in close 
contact  with  REBOV-infected  macaques  and  swine 
[10-12].
Côte  d’Ivoire  ebolavirus  (CIEBOV)  was  discovered 
during an epizootic (animal epidemic) in chimpanzees in 
the Taï National Park in Côte d’Ivoire in 1994, in the first 
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population [13]. So far, CIEBOV has only caused a single, 
non-fatal human case. In 2007 to 2008 a large outbreak of 
viral  hemorrhagic  fever  with  a  case-fatality  rate  of 
approximately 25% occurred in humans in Uganda. The 
causative agent of this outbreak was identified as a novel 
species of EBOV, Bundibugyo ebolavirus (BEBOV) [14]. 
ZEBOV, and to a lesser extent CIEBOV, are responsible 
for devastating outbreaks in the African great ape popu-
lations, with ZEBOV being associated with the decline in 
great ape populations in the Congo basin [15-17].
Symptoms of Ebolavirus disease usually occur after an 
incubation period ranging from several days to 3 weeks 
[8]. Onset of disease symptoms is sudden and consists of 
fever, headache and muscle and joint pain and progresses 
to include diarrhea, loss of appetite (anorexia), vomiting, 
chest pain, shortness of breath, coughing and a maculo-
papular rash (a skin rash consisting of discoloration and 
raised spots). At the peak of illness hemorrhagic mani  fes-
tations develop, although not in all cases; these include 
blood  in  the  stools  (melena)  or  vomit  (hematemesis), 
small  hemorrhages  under  the  skin  (petechiae),  and 
bleeding from the nose, gums, from venipuncture sites 
and  from  the  conjunctiva  of  the  eye.  Ultimately,  fatal 
cases progress to coma, shock and death [7,18]. Massive 
production of proinflammatory cytokines, the absence of 
type  I  interferon  (IFN)  production,  the  absence  of 
antibody induction and loss of peripheral CD4+ and CD8+ 
T  lymphocytes  are  correlated  with  fatal  outcome  in 
EBOV infections [19-21].
EBOV  forms  a  filamentous  particle  of  uniform 
diameter but variable length and shape (Figure 1). The 
viral envelope is derived from the host cell membrane on 
which  the  EBOV  envelope  glycoprotein  (GP),  which 
mediates entry into the host cell, is expressed. The EBOV 
negative-strand RNA genome contains seven genes and 
is encapsidated by the nucleoprotein (NP). The encap  si-
dated genome, the minor nucleoprotein (VP30), the viral 
polymerase (L) and the polymerase cofactor (VP35) are 
required  for  replication  and  transcription  of  the  viral 
RNA. The matrix protein (VP40) is required for budding 
of  the  virus  particle  from  the  plasma  membrane;  the 
minor matrix protein (VP24) facilitates virus budding [8]. 
GP  is  produced  only  after  translational  editing;  the 
primary  gene  product  of  the  gene  that  encodes  GP  is 
soluble GP (sGP) [8], a nonstructural protein of poorly 
understood  function,  which  was  shown  to  reverse  the 
permeability-increasing  effect  of  TNFα  on  endothelial 
cells and partially restore the endothelial barrier function 
of these cells [22].
Here, we provide an overview of our understanding of 
EBOV pathogenicity and the progress in development of 
Table 1. Chronology of Ebolavirus outbreaks
Year  Location  Virus  Species
1976  Democratic Republic of Congo  ZEBOV  Humans
1976  Sudan  SEBOV  Humans
1977  Democratic Republic of Congo  ZEBOV  Humans
1979  Sudan  SEBOV  Humans
1989-1990  USA  REBOV  Cynomolgus macaques
1992  Italy  REBOV  Cynomolgus macaques
1994  Gabon  ZEBOV  Humans
1994  Ivory Coast  CIEBOV  Chimpanzees, humans
1995  Democratic Republic of Congo  ZEBOV  Humans
1996  Gabon  ZEBOV  Humans
1996  Gabon  ZEBOV  Humans
1996  USA  REBOV  Cynomolgus macaques
2000-2001  Uganda  SEBOV  Humans
2001-2002*  Gabon  ZEBOV  Humans, gorillas, duikers
2001-2005*  Republic of Congo  ZEBOV  Humans, gorillas, chimpanzees, duikers
2004  Sudan  SEBOV  Humans
2007-2008*  Republic of Congo  ZEBOV  Humans
2007-2008  Uganda  BEBOV  Humans
2008  Philippines  REBOV  Swine
*Multiple independent outbreaks. Abbreviations: BEBOV, Bundibugyo ebolavirus; CIEBOV, Côte d’Ivoire ebolavirus; REBOV, Reston ebolavirus; SEBOV, Sudan ebolavirus; 
ZEBOV, Zaire ebolavirus.
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of EBOV infection. We also discuss the potential role of 
genomics in EBOV research.
Determinants of pathogenicity
Apart from direct tissue damage resulting from EBOV 
replication,  the  severity  of  EBOV  disease  also  results 
from  indirect  effects  of  virus  replication,  such  as  the 
induction of proinflammatory cytokines, depletion of T 
lymphocytes  and  coagulation  abnormalities.  In  experi-
mental infection of cynomolgus macaques, it was shown 
that the disseminated intravascular coagulation observed 
in patients is most likely not a direct result of replication 
of  EBOV  in  endothelial  cells  [23].  Instead,  in  vitro 
experiments  showed  that  GP  causes  endothelial  cell 
activation, as indicated by upregulation of cell adhesion 
molecules, and a decrease in endothelial barrier function, 
potentially leading to edema and shock [22]. The mucin 
domain of GP, a highly glycosylated region, has a dual 
effect in counteracting host adaptive immunity: not only 
does the mucin domain shield epitopes on GP that could 
otherwise  be  recognized  by  antibodies,  it  also  shields 
major  histocompatibility  complex  I  molecules,  thereby 
impairing antigen presentation by the host cell [24,25]. 
Another  effect  of  GP  on  the  host  adaptive  immune 
response is the presence of a 17-mer peptide that causes 
apoptosis of CD4+ and CD8+ cells in vitro [26]. Besides 
adaptive immunity, GP also affects the innate immune 
system  by  inducing  proinflammatory  cytokines  and 
suppressor  of  cytokine  signaling  1  (SOCS1)  through 
interacting with Toll-like receptor 4 [27]. GP counters the 
host antiviral activity of tetherin (also known as Bst-2 or 
CD317), which retains virus particles at the cell surface 
after budding, through a direct interaction of GP with 
tetherin [28] (Figure 1).
VP24 and NP were shown to be important deter  mi-
nants  of  pathogenicity  in  vivo;  mutations  in  these 
proteins were responsible for adaptation of ZEBOV to 
mice [29] and guinea pigs [30] through their ability to 
counteract  the  IFN-induced  innate  immune  response 
[29] (Figure 1). Although it is not clear how NP counter-
acts the innate immune response, it has been shown in 
experiments  in  vitro  that  VP24  prevents  IFN-α/β-
induced  gene  expression  and  counteracts  the  antiviral 
effects of IFN-β by interacting with karyopherin-α1 (also 
known  as  importin-α)  [31].  Karyopherin-α1  mediates 
nuclear  import  and,  by  interacting  with  this  protein, 
VP24 prevents nuclear accumulation of phosphorylated 
Figure 1. Determinants of Ebolavirus pathogenicity. Schematic representation of an Ebolavirus particle. The roles of GP, NP, VP24 and VP35 in the 
pathogenesis of EBOV, as discussed in the main text, are indicated.
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(STAT1)  [31],  thereby  preventing  IFN-induced  cell 
signal  ing. Two regions of VP24 are involved in the inter-
action with karyopherin-α1 and counteracting the innate 
immune response: residues 42 and 142-146 [32].
VP35  functions  as  an  important  determinant  of 
pathogenicity through blocking IFN-α/β production [33] 
(Figure 1). In vitro, VP35 prevents the activation of inter-
feron regulatory factor 3 (IRF-3) by blocking the virus-
induced  phosphorylation  of  this  protein  [34].  IRF-3 
phosphorylation  is  blocked  by  VP35  through  several 
mechanisms. First, VP35 binds to double-stranded (ds)
RNA,  through  residues  309  and  312  [35,36],  thereby 
preventing dsRNA-mediated activation of retinoic acid-
inducible gene 1 (RIG1), which would normally result in 
phosphorylation and nuclear translocation of IRF-3 and 
subsequently  expression  of  the  IFN-α/β  genes  [35]. 
Second,  VP35  is  phosphorylated  by  κB  kinase  epsilon 
(IKK-ε)  and  TANK-binding  kinase  1  (TBK-1),  thereby 
impair  ing the interaction of these kinases with their sub-
strates IRF-3 and IRF-7 and preventing their phosphory-
lation  [37].  Finally,  through  an  interaction  with  the 
protein  inhibitor  of  activated  STAT1  (PIAS1)  and  the 
ubiquitin-conjugating enzyme Ubc9, VP35 is involved in 
the  SUMOylation  of  IRF-3  and  IRF-7,  resulting  in 
decreased transcription of the IFN-β gene [38].
The ability of VP35 to bind dsRNA also prevents the 
phosphorylation  of  dsRNA-regulated  protein  kinase  R 
(PKR), which would otherwise result in the phosphory-
lation  of  translation  initiation  factor  eIF-2α  and  thus 
block  protein  synthesis  [39,40].  Whether  the  block  of 
PKR  phosphorylation  is  achieved  through  dsRNA 
binding  of  the  amino-  or  carboxy-terminal  domain  of 
VP35 is not clear [39,40]. Yet another in vitro effect of the 
ability of the carboxyl terminus of VP35 to bind dsRNA is 
the suppression of RNA silencing [41]. The importance of 
dsRNA  binding  of  VP35  in  vivo  was  shown  in  guinea 
pigs; in these animals, a virus with mutations at residues 
319 and 322 that no longer bound dsRNA was avirulent, 
whereas the wild-type virus was lethal [42].
Finally, it was shown that the amino terminus of VP35 
affects  maturation  of  dendritic  cells.  In  dendritic  cells, 
VP35  suppresses  upregulation  of  co-stimulatory  mole-
cules  and  pro-inflammatory  cytokines  and  attenuates 
their ability to activate CD4+ T cells [43].
Several host genes and proteins that might be involved 
in  the  pathogenicity  of  EBOV  have  been  described.  A 
microarray  analysis  of  human  hepatoblastoma  cells 
showed that, following infection with EBOV, acute-phase 
genes, complement genes and genes involved in regu  la-
tion of coagulation are downregulated [44]. Analysis of 
gene  expression  in  sequential  peripheral  blood  mono-
nuclear cell samples from EBOV-inoculated non-human 
primates (NHPs) showed only very few changes in gene 
expression  in  the  first  days  after  infection;  among  the 
earliest observed changes was an increase in expression 
of IFN-regulated genes from day 2 and 3 after infection 
onwards. From day 4 after infection onwards, a dramatic 
change  in  the  gene  expression  profile  was  observed, 
including  upregulation  of  proinflammatory  cytokines, 
chemokines, TNFα- and NFκB-regulated genes, apoptosis-
regulating genes and fibrin-dissolution genes [45]. More 
specific host proteins involved in EBOV replication have 
also been identified. For instance, it was shown in vitro 
that RhoB and RhoC, members of the small GTP-binding 
RhoGTPase family, enhanced entry of EBOV into cells 
[46]. Inhibition of heat-shock protein 90 (Hsp90) in vitro 
resulted in inhibition of EBOV replication [47]. Further-
more,  it  was  shown  that  a  large  number  of  host  cell 
proteins are incorporated in EBOV particles. Knocking 
down expression of several of these proteins using small 
interfering (si)RNA resulted in reduced viral replication, 
indicating  the  relevance  of  the  incorporation  of  these 
proteins  into  virus  particles  [48].  Understanding  the 
molecular  mechanisms  behind  the  pathogenicity  of 
EBOV  and  identification  of  host  factors  required  for 
efficient EBOV replication can aid in the development of 
therapeutic and prophylactic treatments for EBOV.
EBOV vaccine development
Vaccination  is  considered  one  of  the  primary  control 
strategies for infectious diseases in the human popu  la-
tion; however, no licensed EBOV vaccines are currently 
available. The first attempts to generate EBOV vaccines 
consisted  of  classical  formulations  of  inactivated  virus 
with different adjuvants, such as Ribi adjuvants or lipid 
A-containing liposomes [49-51]. Although some studies 
resulted in protective immunity in rodent models, most 
of  these  strategies  were  not  successful  in  protecting 
NHPs from lethal challenge with EBOV. The relative ease 
with which protection is generated in mouse and guinea 
pig  models  seems  to  have  limited  predictive  value  for 
vaccine  efficacy  in  NHPs,  the  ‘gold  standard’  animal 
model for EBOV [52]. However, these rodent models are 
still valuable for pre-screening vaccine candidates before 
they advance into NHP models.
The lack of success with classical vaccine approaches 
naturally led to the search for effective vaccine formu-
lations based on the latest developments in the field, such 
as viral-vector-based vaccines, DNA vaccines and virus-
like  particles  (VLPs)  in  a  variety  of  prime-boost 
strategies.  The  advantage  of  using  these  novel  vaccine 
approaches  over  the  classical  vaccine  approach  is  the 
more  robust  induction  of  both  innate  and  adaptive 
immune responses, humoral as well as cellular, resulting 
in  a  better  vaccine  efficacy.  Recent  studies  into  the 
correlates of protection against EBOV infection suggest 
that a humoral immune response alone is not sufficient 
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combined with a sufficient activation of the CD4+ and 
CD8+  T  lymphocytes  in  order  to  confer  protection 
[53-57]. The most promising vaccine approaches against 
EBOV infections are discussed below and in Table 2.
DNA vaccines
DNA vaccines are purified plasmid preparations contain-
ing  one  or  more  DNA  sequences  of  the  pathogen  of 
interest that are expressed in the recipient on delivery. A 
DNA vaccine expressing ZEBOV GP elicited a protective 
immune  response  in  mice  [58]  and  partially  protected 
guinea pigs [59]. A prime-boost vaccine strategy of four 
inoculations with DNA vectors encoding ZEBOV GP and 
SEBOV GP and a boost with a recombinant adenovirus 5 
vector expressing ZEBOV GP generated cross-protective 
immunity in NHPs against a heterologous challenge with 
BEBOV  [57].  There  are  currently  no  licensed  DNA 
vaccines  for  use  in  humans;  however,  a  three-plasmid 
DNA vaccine encoding ZEBOV GP, SEBOV GP and NP 
elicited  a  cellular  and  humoral  immune  response  in 
humans  after  three  injections  of  vaccine  in  a  phase  I 
clinical  trial  [60].  Several  veterinary  DNA  vaccines 
against various viruses are currently licensed, including a 
DNA vaccine for West Nile virus in horses [61].
Recombinant viral vector vaccines
Recombinant viral vaccine vectors can consist of vectors 
capable of replication or of replication-deficient vectors. 
The adenoviral vector is a replication-deficient vaccine 
vector  with  a  broad  cellular  tropism  used  in  a  wide 
variety of gene therapy studies. As mentioned above, a 
combination  of  a  DNA  vaccine  prime  and  adenovirus 
vector  boost  was  able  to  protect  NHPs  from  lethal 
BEBOV challenge [57]. In addition, the incorporation of 
ZEBOV  and  SEBOV  GP  in  a  single  adenovirus  vector 
provided complete protection in NHPs against ZEBOV 
and  SEBOV  challenge,  demonstrating  the  potential  of 
generating immunity against different EBOV species in 
NHPs  [62].  A  recently  completed  phase  I  clinical  trial 
showed that recombinant adenovirus serotype 5 express-
ing ZEBOV and SEBOV GP was safe for use in humans 
[63].
The use of replication-competent vector-based vaccines 
has been very successful in the development of veterinary 
vaccines; ten recombinant poultry vaccines are currently 
licensed [64]. For EBOV, replication competent recom  bi-
nant vesicular stomatitis virus (rVSV) vectors expressing 
EBOV genes have been generated successfully. A single 
administration of rVSV expressing ZEBOV GP elicited 
complete  protection  of  NHPs  from  homologous  chal-
lenge, but not from heterologous SEBOV challenge [65]. 
A multivalent vaccine composed of equal parts of rVSV 
expressing GPs of Marburgvirus (MARV), ZEBOV and 
SEBOV offered protection against challenge with MARV, 
ZEBOV,  SEBOV  and  CIEBOV  in  NHPs  [66].  Another 
important potential of the rVSV-based EBOV vaccines is 
their use as post-exposure treatment. When rVSV with 
ZEBOV GP or SEBOV GP was administered to NHPs 30 
minutes  after  homologous  EBOV  challenge,  the  rVSV 
vaccine  was  able  to  protect  50%  of  ZEBOV-infected 
animals  and  100%  of  SEBOV-infected  animals  [67,68]. 
The  rVSV  ZEBOV  GP  was  recently  used  to  contain  a 
potential  laboratory  exposure  with  ZEBOV  and  was 
administered 40 hours after the incident [69].
Another  replication-competent  viral  vector,  human 
parainfluenza virus type 3 (HPIV3) expressing ZEBOV 
GP,  was  highly  immunogenic  after  two  intranasal 
Table 2. Promising vaccine and antiviral drug development for the prevention and treatment of Ebolavirus
Treatment  Efficacy  Prophylactic  Therapeutic  Status  References
Vaccines
DNA vaccines  Rodents and NHPs  Yes  Unknown  Phase I clinical trails  [57,60]
Adenovirus  Rodents and NHPs  Yes  Unknown  Phase I clinical trails  [62,63]
rVSV-EBOV  Rodents and NHPs  Yes  Yes  Experimental  [65-68]
HPIV3-EBOV  Rodents and NHPs  Yes  Unknown  Experimental  [70]
EBOV-VLPs  Rodents and NHPs  Yes  Unknown  Experimental  [71]
Replication-deficient ZEBOV  Rodents  Yes  Unknown  Experimental  [72]
Antivirals
rhAPC  Partial in NHPs  Unknown  Yes  Licensed*  [75]
rNAPc2  Partial in NHPs  Yes  Yes  Phase II clinical trials†  [76]
FGI-103, FGI-104 and FGI-106  Rodents  Yes  Yes‡  Experimental  [81-83]
Antisense oligonucleotides  Rodents and NHPs  Yes  Yes  Experimental  [85-88]
*Licensed for the treatment of sepsis-induced coagulation disorders. †The antithrombotic potential of rNAPc2 in orthopedic surgery and coronary revascularization 
was tested. ‡Only FGI-106 was tested therapeutically. Abbreviations: HPIV3, human parainfluenza virus type 3; NHP, non-human primate; rhAPC, recombinant human 
activated protein C; rNAPc2, nematode anticoagulant protein c2; rVSV, recombinant vesicular stomatitis virus; VLP, virus-like particle.
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challenge [70].
Virus-like particle vaccines
VLPs are particles generated by the expression of one or 
more viral proteins and mimic the natural viral confor-
mation but do not contain viral genetic material. EBOV 
VLPs were generated by simultaneously express  ing GP, 
NP and VP40 of ZEBOV in 293T cells, combined with 
Ribi  adjuvant  and  administered  three  times  to  NHPs, 
resulting  in  protection  against  homologous  ZEBOV 
challenge [71]. Another vaccine candidate recently investi-
gated  was  a  replication-deficient  ZEBOV  lacking  the 
VP30 gene. Two vaccinations with this virus protected 
mice and guinea pigs from lethal ZEBOV challenge [72].
Although there are now promising vaccine candidates, 
the  correlates  of  protection  from  EBOV  infection  are 
still  poorly  understood.  Combining  existing  vaccine 
candi  dates with research into the correlates of protec-
tion and applying genomics strategies should result in 
improved vaccines effective as post-exposure treatment 
and/or  vaccines  that  cross-protect  against  all  four 
African EBOV.
Development of EBOV antiviral therapeutics
There has been an active search for effective therapeutic 
treatments for EBOV infection; unfortunately, these have 
so far had limited success (Table 2). Licensed therapeutics 
for  the  treatment  of  other  viral  infections,  such  as 
IFN-α2b  and  ribavirin  (used  for  the  treatment  of,  for 
example, hepatitis B and C virus) did not show prophy-
lactic  or  therapeutic  value  for  the  treatment  of  EBOV 
[73,74].  Limited  therapeutic  efficacy  was  seen  with 
recom  binant human activated protein C (rhAPC), a drug 
licensed for the treatment of sepsis-induced coagulation 
disturbances: two out of eleven NHPs survived a lethal 
ZEBOV challenge and there was a significant increase in 
time to death [75]. More promising results were obtained 
using  nematode  anticoagulant  protein  c2  (rNAPc2),  a 
drug  under  evaluation  for  treatment  of  coagulation 
abnormalities through inhibition of the fVIIa tissue factor 
complex. rNAPc2 was able to protect three out of nine 
NHPs  after  a  lethal  ZEBOV  challenge  using  both 
prophylactic  (10  minutes  before  challenge)  and  post-
exposure  (24  hours  after  challenge)  treatment  regimes 
[76]. Pre-exposure treatment of NHPs with a neutralizing 
monoclonal  antibody  failed  to  protect  them  when 
challenged with a lethal dose of ZEBOV [77].
The discovery of effective EBOV antiviral compounds 
has  been  hampered  by  the  need  for  biosafety  level  4 
(BSL4) facilities to work safely with EBOV and the lack of 
high-throughput  screening  technologies.  The  develop-
ment of alternative screening strategies, such as the use 
of VLPs and pseudotyped VSV, as well as of minigenome 
systems, has enabled the screening of compound libraries 
in a high-throughput manner at lower containment level 
(BSL2).  In  addition,  the  increased  number  of  BSL4 
labora  tories combined with the development of reverse 
genetics  technologies  for  EBOV  [78],  leading  to  the 
creation of EBOV expressing green fluorescent protein 
(EBOV-GFP)  [79,80],  has  enabled  high-throughput 
screening of anti-EBOV compounds within high contain-
ment laboratories.
High-throughput antiviral drug screening
The screening of compound libraries using EBOV-GFP 
has identified several compounds showing in vitro and in 
vivo antiviral activity. The antiviral compounds FGI-103, 
FGI-104  and  FGI-106  showed  in  vivo  efficacy  against 
ZEBOV  in  a  mouse  model  following  treatment  before 
and throughout the remainder of the study with these 
compounds  [81-83].  FGI-106  also  conferred  complete 
protection  to  mice  challenged  with  ZEBOV  when 
administered from the time of challenge onwards, and 
90% protection with post-exposure treatment [81]. EBOV 
enters the host cell by fusion of the viral envelope and the 
host cell membrane. Given that several other enveloped 
viruses use a similar process, this allows the development 
of  compounds  with  broad-spectrum  antiviral  activity. 
One  such  molecule,  LJ001,  was  discovered  using  a 
pseudotyped VSV virus with a luciferase reporter [84]. 
LJ001 binds to the virus envelope and inhibits virus-cell 
fusion for a large range of enveloped viruses, including 
EBOV. Pretreatment of mice with LJ001 reduced ZEBOV 
mortality by 80%, but the compound did not show any 
efficacy in a post-challenge model, presumably as a result 
of limited bioavailability [84].
Antisense therapy
Currently, the most promising studies in antiviral treat-
ment  of  EBOV  use  the  ability  of  virus-gene-specific 
oligo  nucleotides  to  interfere  with  translation  of  viral 
mRNA.  This  antisense  strategy  inhibits  EBOV  replica-
tion, resulting in a reduction in the pathogenic effects of 
EBOV and allowing the immune system more time to 
clear  the  infection.  A  combination  antisense  strategy 
targeted at ZEBOV L, VP24 and VP35 was an efficacious 
post-exposure  treatment  in  several  rodent  and  NHP 
studies  [85-88].  Depending  on  the  time  of  intravenous 
treatment, 66% or 100% of NHPs were protected from 
lethal challenge [86]. A similar study, using chemically 
modified  oligonucleotides  called  phosphorodiamidate 
morpho  lino oligomers, conferred 60% protection against 
lethal  ZEBOV  challenge  in  NHPs  following  intra-
peritoneal, subcutaneous and intravenous administration. 
Although the 30- to 60-minute interval between ZEBOV 
challenge and the start of the therapeutic treatment used 
in  both  studies  indicates  the  potential  of  antisense 
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feasibility for effective use in an outbreak setting remains 
to be determined.
Future perspectives
In the past decade, there has been significant progress in 
the  general  understanding  of  EBOV  replication  and 
pathogenesis. The increased availability of BSL4 facilities 
and the development of molecular tools to study parts of 
the basic biology of EBOV under BSL2 conditions will 
undoubtedly  lead  to  a  more  comprehensive  under-
standing  of  EBOV  in  the  near  future.  The  increasing 
capability and capacity of tools such as mRNA expression 
profiling, high-throughput and 454 sequencing and RNA 
interference technologies have greatly contributed to our 
knowledge  in  biomedical  research,  including  virology. 
These new technologies have been rapidly implemented 
in fundamental and clinical research settings. The broad 
range of applications in virology of these new genomic 
technologies  encompasses  areas  such  as  epidemiology, 
viral pathogenesis, host response and the development of 
diagnostics, vaccines, and antivirals. However, in com-
pari  son with other viral pathogens, such as influenza A 
virus  and  HIV,  research  of  EBOV  has  only  marginally 
benefitted from these developments. A more extensive 
use of genomic and post-genomic approaches in EBOV 
research will probably result in a rapid advance in our 
understanding  of  EBOV  pathogenesis  and  virus-host 
interactions, such as receptor usage, viral replication or 
interactions with innate and adaptive immune responses. 
The identification of interactions of EBOV with host cell 
factors,  such  as  Hsp90,  and  other  potential  targets  for 
therapeutic intervention [46-48] may result in targeted 
design of antiviral therapeutics [89]. Likewise, the availa-
bility of EBOV genomic sequences and under  standing of 
the  virus  replication  cycle  may  allow  novel  vaccine 
approaches,  such  as  ‘reverse  vaccinology’  [90].  Future 
EBOV research should therefore focus on understanding 
the cellular processes involved in EBOV replication and 
pathogenesis,  using  broad  genomics  and  proteomics 
approaches,  combining  data  obtained  in  experimental 
settings in vitro and in vivo.
Whereas  the  screening  of  compound  libraries  has 
yielded  promising  candidates  with  potent  antiviral 
characteristics, the solving of crystal structures of EBOV 
proteins  and  their  associated  biological  function  will 
hopefully result in the rational design of antiviral drugs, 
similar to antivirals used for the treatment of HIV and 
influenza A virus [91-94]. Moreover, in the absence of 
vaccines or antivirals directed at EBOV, research should 
be aimed at interfering with the indirect effects of EBOV 
replication,  such  as  modulating  the  innate  immune 
response  and  preventing  lymphocyte  depletion  and 
coagulation abnormalities.
Here, we have highlighted several promising candidates 
for vaccine and antiviral use (Table 2). In the light of the 
severity of EBOV disease and the observed increase in 
outbreaks over the past decade, the expedited translation 
of these potential candidate therapeutics from bench to 
bedside  is  of  the  utmost  importance.  The  severity  of 
EBOV  disease  and  the  sporadic  nature  of  outbreaks 
render normal phase III efficacy trials neither ethical nor 
feasible. However, the availability of the so-called ‘animal 
rule’ allows the licensing of vaccines or antivirals on the 
basis of evidence in well-characterized animal models, in 
addition to the phase I and phase II requirements [95-97]. 
Therefore,  it  is  crucial  to  validate  the  existing  NHP 
models  with  respect  to  their  feasibility  to  function  as 
models  for  human  EBOV  infection.  In  addition,  it  is 
crucial  to  obtain  more  in-depth  knowledge  on  the 
correlates of protection against EBOV infection, both for 
vaccines and antivirals, using genomics and proteomics 
approaches, which will allow a more targeted vaccine and 
antiviral design approach.
Lastly, clear identification of the target populations for 
the various therapeutic intervention strategies is neces-
sary.  Whereas  most  of  the  discussed  post-exposure 
vaccine  and  antiviral  therapeutic  strategies  will  be 
particularly useful in laboratory incidents and outbreak 
situations,  prophylactic  vaccine  strategies  targeting  the 
rural populations in EBOV endemic regions in general 
are questionable. Specific targeting of certain risk groups 
or  ring  vaccination  (vaccination  of  all  individuals  in  a 
prescribed area around an outbreak) approaches during 
outbreaks seem more feasible but would still require a 
combined international effort to ensure the deployment 
of  available  vaccines  where  most  needed.  Moreover, 
although  the  focus  of  the  therapeutic  intervention 
strategies has been largely on preventing EBOV disease 
in  humans,  similar  approaches  are  urgently  needed  to 
prevent the introduction and spread of EBOV into the 
endangered  gorilla  and  chimpanzee  populations  of 
Central Africa, which could be pushed to the brink of 
extinction by EBOV outbreaks.
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